Global Colon Cancer Association shared a post on LinkedIn:
“NTRK gene fusion is a rare but clinically actionable biomarker in colorectal cancer. Fewer than 1% of CRCs harbor an NTRK fusion, but in MSI-High tumors without KRAS, NRAS, or BRAF mutations, prevalence ranges from 5–44%.
When NTRK fusion is identified, patients may benefit from TRK inhibitor therapy – larotrectinib (Vitrakvi), entrectinib (Rozlytrek), or repotrectinib (Augtyro). These are tumor-agnostic therapies, approved across cancer types based on the presence of the biomarker rather than tumor origin.”
Other articles from Global Colon Cancer Association.